Safety and tolerability during the placebo-controlled period
TEAEs
ADVERSE EVENTS, SECONDARY
In the DBTP, treatment-emergent adverse events (TEAEs) occurred in 71.4% and 68.8% of evinacumab- and placebo-treated patients, respectively (secondary end point). Common TEAEs occurring in >5% of patients in any treatment group are detailed in Table Summary of TEAEs in any treatment group during the DBTP